Company Overview and News
2018-09-14 seekingalpha - 1
REITs are unique in terms of their ability to grow moats; there are essentially two valuable levers that the company can (and should) utilize to build competitive advantage.
JCP DCT OPRF PSA.A CVS SHLD AMT EQY PSB ROST PSA EQIT WPC DRE KDNUU SBRA PSAXZ CCP VTR PPS COST O KND PLD
A little late with this post as I like to highlight my potential stock buys in the beginning of the month but sometimes it can be tough deciding where to deploy fresh capital when many stocks are trading at premium prices. Of course, we all know that no matter how high the market rises, there will always be a gem in the rough lurking somewhere. With that being said, let's take a look at some of my September stock considerations.
D HCP PPL SBRA SBRAP
IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company’s Chairman and Chief Executive Officer, Harold Andrews, the company’s Chief Financial Officer, and Talya Nevo-Hacohen, the company’s Chief Investment Officer, will be attending the Bank of America Merrill Lynch Global Real Estate Conference on September 25 - 26 at The Wagner in New York, NY.
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'0O M26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT)R56E%O
Document Table of Contents UNITED ST
IRVINE, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) and PointRight® announced a strategic partnership to provide post-acute analytics to Sabra’s Skilled Nursing Facility (“SNF”) portfolio. Through this partnership, Sabra’s SNF tenants and operators can participate in a collaborative program that provides PointRight’s clinical and business intelligence tools to help them manage and improve outcomes in their facilities.
Recently, Sabra Health Care REIT (SBRA - Free Report) announced the selling of nine healthcare facilities leased to Genesis Healthcare (GEN - Free Report) on Jun 29, in a bid to dispose the properties leased to the latter. These healthcare facilities have been sold for $81.4 million.
CXP PSB SBRA ADI GEN SBRAP
IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that on June 29, 2018, it completed the previously announced sale of nine facilities (seven skilled nursing facilities, one senior housing community and one continuing care retirement community) leased to Genesis Healthcare, Inc. (“Genesis”) for $81.4 million. Under the terms of Sabra’s memoranda of understanding with Genesis, Genesis’s annual rent obligations to Sabra were reduced by $7.
GEN CCP SBRA SBRAP
Each June, the National Association of Real Estate Investment Trusts (NAREIT) hosts a conference that brings all of the key players in the sector together. For REIT investors, it’s the equivalent of the Super Bowl and it offers a window into who’s poised to perform well in the second half of the year and beyond.
SRC SRC.WI RESI SBRA
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET